单株抗体治疗市场 - 全球产业规模、份额、趋势、机会和预测，按产品类型、应用、生产来源、最终用户、地区和竞争细分，2020-2030 年预测

2024 年全球单株抗体治疗市值为 2,430.2 亿美元，预计到 2030 年将达到 4,182.8 亿美元，预测期内的年复合成长率(CAGR) 为 9.43%。近年来，在医学研究和技术的突破性进步的推动下，全球医疗保健领域发生了重大转变。其中，单株抗体（mAb）在治疗领域的开发和应用引起了广泛关注。单株抗体彻底改变了各种疾病的治疗方法，其中低端单株抗体治疗领域正在成为这一充满活力的领域的关键参与者。

单株抗体是一类旨在针对体内特定蛋白质或抗原的生物製药。它们是透过克隆一种称为 B 细胞的单一免疫细胞来产生相同的抗体。这些抗体被设计成与特定分子结合，例如癌细胞、病原体或自体免疫触发因素表面的分子。这种有针对性的方法可以对多种疾病进行精准治疗。

全球低剂量单株抗体治疗市场涵盖广泛的治疗应用，近年来经历了令人瞩目的成长。癌症、自体免疫疾病和传染病等慢性疾病仍然是全球面临的重大健康挑战，单株抗体成为一种有希望的治疗选择。生物技术，特别是抗体工程的进步，导致了更专业和有效的单株抗体的产生，扩大了治疗应用的范围并增加了市场需求。此外，单株抗体是个人化医疗的核心，其治疗根据个人的基因组成和疾病特征量身定制，从而改善治疗效果和患者满意度。

世界各国政府积极支持包括单株抗体疗法在内的生物技术研发，为创新计画提供资金和支持。这对于加速市场成长至关重要。

主要市场驱动因素

主要市场挑战

主要市场趋势

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：顾客之声

第五章：全球单株抗体治疗市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依产品类型（裸露、融合蛋白、抗体片段、结合物、多特异性）
  • 依应用分类（癌症、自体免疫疾病、传染病、其他）
  • 依生产来源分类（人类、人源化、嵌合体、其他）
  • 按最终用户（医院、专科中心、研究机构）
  • 按地区
  • 按公司分类（2024）
• 市场地图

第 6 章：北美单株抗体治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 加拿大
  • 墨西哥

第 7 章：欧洲单株抗体治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 英国
  • 义大利
  • 法国
  • 西班牙

第 8 章：亚太地区单株抗体治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 印度
  • 日本
  • 韩国
  • 澳洲

第 9 章：南美洲单株抗体治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲单株抗体治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 合併与收购（如有）
• 产品发布（如果有）
• 最新动态

第 13 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 14 章：竞争格局

• F. Hoffmann-La Roche Ltd
• Novartis AG
• Merck & Co. Inc.
• Pfizer Inc.
• Eli Lilly and Co. (Lilly)
• Sanofi SA
• AstraZeneca Plc
• Bayer AG
• Regeneron Pharmaceuticals Inc.
• GSK Plc

第 15 章：策略建议

第16章 调査会社について・免责事项

The global monoclonal antibody therapeutics market was valued at USD 243.02 billion in 2024 and is projected to reach USD 418.28 billion by 2030, reflecting a compound annual growth rate (CAGR) of 9.43% during the forecast period. Recent years have seen a significant transformation in the global healthcare sector, driven by groundbreaking advancements in medical research and technology. Among these, the development and application of monoclonal antibodies (mAbs) in therapeutics has garnered significant attention. Monoclonal antibodies have revolutionized the treatment of various diseases, with the lower monoclonal antibody therapeutics segment emerging as a key player within this dynamic field.

Monoclonal antibodies are a class of biopharmaceuticals designed to target specific proteins or antigens in the body. They are created by cloning a single type of immune cell, known as a B cell, to produce identical antibodies. These antibodies are engineered to bind with particular molecules, such as those found on the surface of cancer cells, pathogens, or autoimmune triggers. This targeted approach enables precise treatment for a wide array of diseases.

The global lower monoclonal antibody therapeutics market encompasses a broad spectrum of therapeutic applications and has experienced impressive growth in recent years. Chronic diseases, such as cancer, autoimmune disorders, and infectious diseases, remain a significant global health challenge, with monoclonal antibodies emerging as a promising treatment option. Advancements in biotechnology, particularly in antibody engineering, have led to the creation of more specialized and effective monoclonal antibodies, expanding the range of therapeutic applications and increasing market demand. Furthermore, monoclonal antibodies are central to personalized medicine, where treatments are tailored to an individual's genetic makeup and disease profile, improving both treatment outcomes and patient satisfaction.

Governments worldwide are actively supporting research and development in biotechnology, including monoclonal antibody therapeutics, by providing funding and support for innovative projects. This has been pivotal in accelerating market growth.

Key Market Drivers

The rising prevalence of chronic diseases has been a major driver for the global monoclonal antibody therapeutics market. Over recent years, there has been a notable increase in the prevalence of chronic diseases, including cancer, autoimmune disorders, and infectious diseases. This surge has amplified the demand for effective and advanced treatment options, spurring growth in the monoclonal antibody therapeutics market. Monoclonal antibodies, with their targeted approach, offer promising biopharmaceutical therapies for these chronic conditions.

Chronic diseases, characterized by their long-term duration and slow progression, now account for a substantial portion of the global disease burden. Contributing factors include an aging population, sedentary lifestyles, poor dietary habits, and increased exposure to risk factors such as tobacco and alcohol. Environmental, genetic, and infectious factors also play significant roles in the development of these illnesses. As the incidence of chronic diseases rises, the demand for innovative and effective treatments is more pressing than ever.

The monoclonal antibody therapeutics market has witnessed remarkable growth, driven by the increasing acceptance of these therapies in clinical practice. Pharmaceutical companies and research institutions are heavily investing in developing novel monoclonal antibody therapies for chronic diseases, resulting in a robust pipeline of potential treatments. Additionally, regulatory agencies like the U.S. Food and Drug Administration (FDA) are approving more monoclonal antibody drugs, expanding their clinical use.

Key Market Challenges

A significant challenge facing the monoclonal antibody therapeutics market is the high cost of research, development, and clinical trials. The process of discovering and designing monoclonal antibodies is both time-consuming and expensive, requiring substantial financial investment. From early-stage research to clinical trials, these therapies undergo rigorous testing to meet safety and efficacy standards set by regulatory authorities. Compliance with regulatory requirements and the extensive documentation required for approval further increases costs. These high development costs often pose a barrier to entry for smaller biotech companies, limiting their ability to introduce new therapeutic options to the market.

Additionally, continuous research efforts to improve existing therapies and develop next-generation monoclonal antibodies further strain financial resources. As a result, larger, well-funded companies tend to dominate the market, consolidating industry power among the major players.

Key Market Trends

Technological advancements have significantly propelled the growth of the monoclonal antibody therapeutics market. In recent years, progress in genomics, proteomics, and bioinformatics has revolutionized the identification of disease-related targets, enabling more accurate development of monoclonal antibody therapies. Technologies such as phage display allow rapid screening of large antibody libraries to identify the most effective candidates for therapeutic purposes.

Moreover, advancements in antibody engineering have led to the creation of humanized and fully human antibodies, minimizing the risk of immune responses and expanding the potential patient population. Innovations in bioprocessing and cell culture techniques have enhanced the scalability and efficiency of monoclonal antibody production, reducing manufacturing costs and increasing accessibility to these therapies. The development of bioconjugation techniques has further enhanced the market, enabling the creation of antibody-drug conjugates (ADCs) that show promise in treating cancer and other diseases.

Key Market Players

• F. Hoffmann-La Roche Ltd.
• Novartis AG
• Merck & Co., Inc.
• Pfizer Inc.
• Eli Lilly and Co. (Lilly)
• Sanofi S.A.
• AstraZeneca Inc.
• Bayer AG
• Regeneron Pharmaceuticals Inc.
• GSK Plc.

Market Segmentation

The global monoclonal antibody therapeutics market is segmented as follows:

By Product Type:

• Others
• Naked
• Fusion Protein
• Antibody Fragment
• Conjugate
• Multi-specific

By Application:

• Cancer
• Autoimmune Diseases
• Infectious Diseases
• Others

By Production Source:

• Human
• Humanized
• Chimeric
• Others

By End User:

• Hospitals
• Specialty Centers
• Research Institutes

By Region:

• North America: United States, Canada, Mexico
• Europe: France, United Kingdom, Italy, Germany, Spain
• Asia-Pacific: China, India, Japan, Australia, South Korea
• South America: Brazil, Argentina, Colombia
• Middle East & Africa: South Africa, Saudi Arabia, UAE

Competitive Landscape

The report also provides a detailed analysis of the major companies in the monoclonal antibody therapeutics market, with the option for further customization based on specific business needs.

Available Customizations

TechSci Research offers the following customization options for the global monoclonal antibody therapeutics market report:

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Monoclonal Antibody Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product Type (Naked, Fusion Protein, Antibody Fragment, Conjugate, Multi-specific)
  • 5.2.2. By Application (Cancer, Autoimmune Diseases, Infectious Diseases, Others)
  • 5.2.3. By Production Source (Human, Humanized, Chimeric, Others)
  • 5.2.4. By End User (Hospital, Specialty Centers, Research Institutes)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Monoclonal Antibody Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product Type
  • 6.2.2. By Application
  • 6.2.3. By Production Source
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Monoclonal Antibody Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By Production Source
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Monoclonal Antibody Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By Production Source
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Monoclonal Antibody Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By Production Source
      • 6.3.3.2.4. By End User

7. Europe Monoclonal Antibody Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product Type
  • 7.2.2. By Application
  • 7.2.3. By Production Source
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Monoclonal Antibody Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By Production Source
      • 7.3.1.2.4. By End User
  • 7.3.2. United Kingdom Monoclonal Antibody Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By Production Source
      • 7.3.2.2.4. By End User
  • 7.3.3. Italy Monoclonal Antibody Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By Production Source
      • 7.3.3.2.4. By End User
  • 7.3.4. France Monoclonal Antibody Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By Production Source
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Monoclonal Antibody Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By Production Source
      • 7.3.5.2.4. By End User

8. Asia-Pacific Monoclonal Antibody Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product Type
  • 8.2.2. By Application
  • 8.2.3. By Production Source
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Monoclonal Antibody Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By Production Source
      • 8.3.1.2.4. By End User
  • 8.3.2. India Monoclonal Antibody Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By Production Source
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Monoclonal Antibody Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By Production Source
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Monoclonal Antibody Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product Type
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By Production Source
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Monoclonal Antibody Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product Type
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By Production Source
      • 8.3.5.2.4. By End User

9. South America Monoclonal Antibody Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product Type
  • 9.2.2. By Application
  • 9.2.3. By Production Source
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Monoclonal Antibody Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By Production Source
      • 9.3.1.2.4. By End User
  • 9.3.2. Argentina Monoclonal Antibody Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By Production Source
      • 9.3.2.2.4. By End User
  • 9.3.3. Colombia Monoclonal Antibody Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By Production Source
      • 9.3.3.2.4. By End User

10. Middle East and Africa Monoclonal Antibody Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product Type
  • 10.2.2. By Application
  • 10.2.3. By Production Source
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Monoclonal Antibody Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By Production Source
      • 10.3.1.2.4. By End User
  • 10.3.2. Saudi Arabia Monoclonal Antibody Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By Production Source
      • 10.3.2.2.4. By End User
  • 10.3.3. UAE Monoclonal Antibody Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By Production Source
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. F. Hoffmann-La Roche Ltd
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Novartis AG
• 14.3. Merck & Co. Inc.
• 14.4. Pfizer Inc.
• 14.5. Eli Lilly and Co. (Lilly)
• 14.6. Sanofi S.A.
• 14.7. AstraZeneca Plc
• 14.8. Bayer AG
• 14.9. Regeneron Pharmaceuticals Inc.
• 14.10. GSK Plc

15. Strategic Recommendations

16. About Us & Disclaimer